Abstract | OBJECTIVE: To evaluate the efficacy of lurasidone for schizophrenia using an established five-factor model of the Positive and Negative Syndrome Scale (PANSS). METHODS: Patient-level data were pooled from five randomized, double-blind, placebo-controlled, 6-week studies of lurasidone (fixed doses, 40-160mg/d) for patients with an acute exacerbation of schizophrenia. Changes in five established PANSS factors were assessed using mixed-model repeated measures analysis. RESULTS: Compared with placebo (n=496), lurasidone (n=1029, dose groups pooled) significantly improved the PANSS total score at Week 6 (-22.6 vs. -12.8; P<0.001; effect size, 0.45), as well as all factor scores (P<0.001 for each): positive symptoms (-8.4 vs. -6.0; effect size, 0.43), negative symptoms (-5.2 vs. -3.3; effect size, 0.33), disorganized thought (-4.9 vs. -2.8; effect size, 0.42), hostility/excitement (-2.7 vs. -1.6; effect size, 0.31), and depression/anxiety (-3.2 vs. -2.3; effect size, 0.31). Separation from placebo occurred at Week 1 for the positive symptoms, disorganized thought, and hostility/excitement factors and at Week 2 for the other factors. CONCLUSIONS: In this pooled analysis of short-term studies in patients with acute schizophrenia, lurasidone demonstrated significant improvement for each of the five PANSS factor scores, indicating effectiveness across the spectrum of schizophrenia symptoms.
|
Authors | A Loebel, J Cucchiaro, R Silva, Y Mao, J Xu, A Pikalov, S R Marder |
Journal | European psychiatry : the journal of the Association of European Psychiatrists
(Eur Psychiatry)
Vol. 30
Issue 1
Pg. 26-31
(Jan 2015)
ISSN: 1778-3585 [Electronic] England |
PMID | 25280429
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier Masson SAS. |
Chemical References |
- Antipsychotic Agents
- Lurasidone Hydrochloride
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Lurasidone Hydrochloride
(therapeutic use)
- Male
- Middle Aged
- Psychiatric Status Rating Scales
- Randomized Controlled Trials as Topic
- Schizophrenia
(drug therapy)
- Schizophrenic Psychology
- Treatment Outcome
|